Aaron Royston, a Managing Partner at venBio Partners, primarily invests in clinical-stage biotechnology. See sector focus and contact routes.
Aaron Royston, a Managing Partner at venBio Partners, primarily invests in clinical-stage biotechnology and pharmaceutical companies developing novel therapeutics for unmet medical needs, with 75% of the firm's investments occurring at the Series A stage. His check size typically ranges from $20 million to $30 million, with the firm deploying average investments of $30–$70 million per company across sectors including oncology, immunology, rare diseases, and radiopharmaceuticals. Royston's distinctive thesis focuses on backing companies—whether asset-based or platform-driven—that can reach a meaningful milestone within a three-to-five-year horizon, and he has directed investments in notable portfolio companies such as Apellis Pharmaceuticals, Akero Therapeutics, and RayzeBio (acquired by Bristol Myers Squibb for $4.1 billion).
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Aaron Royston · Full investor directory · Investor access · Company funding database